Rapport Therapeutics, Inc. Common Stock (RAPP) - Total Assets
Based on the latest financial reports, Rapport Therapeutics, Inc. Common Stock (RAPP) holds total assets worth $497.60 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See RAPP equity financing ratio to measure how much of total assets are equity-financed.
Rapport Therapeutics, Inc. Common Stock - Total Assets Trend (2022–2025)
This chart illustrates how Rapport Therapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Check Rapport Therapeutics, Inc. Common Stock tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Rapport Therapeutics, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Rapport Therapeutics, Inc. Common Stock's total assets of $497.60 Million consist of 97.3% current assets and 2.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 10.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Rapport Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Rapport Therapeutics, Inc. Common Stock stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Rapport Therapeutics, Inc. Common Stock's current assets represent 97.3% of total assets in 2025, a decrease from 98.9% in 2022.
- Cash Position: Cash and equivalents constituted 10.3% of total assets in 2025, down from 98.6% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Rapport Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of Rapport Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Rapport Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 27.08 | 31.01 | 17.14 |
| Quick Ratio | 27.08 | 31.01 | 17.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $466.80 Million | $281.58 Million | $142.07 Million |
Rapport Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Rapport Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.50 |
| Latest Market Cap to Assets Ratio | 3.49 |
| Asset Growth Rate (YoY) | 62.7% |
| Total Assets | $512.43 Million |
| Market Capitalization | $1.79 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Rapport Therapeutics, Inc. Common Stock's assets at a significant premium (3.49x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Rapport Therapeutics, Inc. Common Stock's assets grew by 62.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Rapport Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual total assets of Rapport Therapeutics, Inc. Common Stock from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $512.43 Million | +62.71% |
| 2024-12-31 | $314.93 Million | +102.63% |
| 2023-12-31 | $155.42 Million | +391.80% |
| 2022-12-31 | $31.60 Million | -- |
About Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containin… Read more